L. helveticus

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: stress mood sleep

Research Overview

Across the abstracts provided, Lactobacillus helveticus has been studied most often in (1) gastrointestinal infections/acute gastroenteritis in children (typically as part of a multi-strain product), (2) immunomodulatory mechanisms in vitro (human macrophage models assessing ROS, cytokines, phagocytosis, NF-κB/TLR2 signaling), and (3) preclinical models of systemic or organ injury where oxidative stress and inflammation are central (e.g., cadmium-induced intestinal and lung toxicity). A separate, more applied line of work examines dairy/food-technology properties of L. helveticus, particularly strain-dependent exopolysaccharide (EPS) production and its effects on fermented milk texture and gel microstructure. Several abstracts also point to “psychobiotic”/gut–brain axis and gut–liver axis (NAFLD) applications, but the provided text is incomplete and does not allow firm conclusions about outcomes or effect sizes in those domains.

The strongest evidence in the provided set is mixed and is most definitive where high-quality human trials show lack of clinical benefit: a large randomized, double-blind pediatric emergency-department trial found that a 5-day course of a combined probiotic containing L. rhamnosus R0011 and L. helveticus R0052 did not reduce moderate-to-severe gastroenteritis or improve symptom duration versus placebo. Consistent with this, the cited guideline update for pediatric acute gastroenteritis concludes that, despite many trials overall, the evidence base does not support clear benefit for specific probiotic strains with sufficient high-quality replication—indirectly limiting confidence in L. helveticus-containing interventions for this indication. By contrast, mechanistic and animal studies provide supportive but lower-certainty evidence that certain L. helveticus strains can stimulate innate immune responses (e.g., proinflammatory cytokine induction, enhanced phagocytosis/bactericidal activity, NF-κB/TLR2 signaling) and may mitigate oxidative/inflammatory tissue injury in rodents when administered in multi-strain mixtures.

Key gaps include the need for more strain-specific, adequately powered, well-controlled human trials that isolate L. helveticus effects (rather than multi-strain formulations) and use clinically meaningful endpoints across proposed indications (e.g., acute gastroenteritis treatment, IBS-related visceral pain/HPA-axis outcomes, NAFLD, and CNS/gut–brain axis outcomes). Additional research is also needed to connect in vitro immunostimulatory signatures to in vivo clinical benefit and safety, including dose–response relationships, duration of administration, host factors (age, baseline microbiome, pathogen etiology), and mechanistic biomarkers. Finally, while food-technology studies robustly demonstrate strain-to-strain variability in EPS yield and resulting fermented-milk properties, more work is required to determine whether these manufacturing-relevant traits translate into consistent probiotic functionality in humans.

1. What conditions has L. helveticus been studied for?

  • Acute gastroenteritis (AGE) in children: Studied as part of a combination probiotic (L. rhamnosus R0011 + L. helveticus R0052) in a large randomized, double-blind trial in pediatric emergency departments.

  • Guideline-evaluated use in pediatric AGE: Specifically assessed in an evidence-based guideline update, which issued recommendations about L. helveticus R0052 + L. rhamnosus R0011.

  • Cadmium (Cd)-induced toxicity/oxidative stress (animal model): A rat study tested a probiotic mix including L. helveticus (with L. rhamnosus and L. casei) for protection of small intestine and lung from Cd injury.

  • Innate immune activation (cell/immune model): Human macrophage experiments tested L. helveticus (IMAU70129) effects on ROS, cytokines, phagocytosis, bactericidal activity, NF-κB signaling, and TLR2 activation.

  • Vaginal dysbiosis / bacterial vaginosis (BV) symptoms (human pilot): A randomized, double-blind, placebo-controlled pilot of a multi-Lactobacillus vaginal suppository found L. helveticus as an “indicator species” associated with microbiome changes after treatment.

  • Visceral pain / stress-related gut-brain axis outcomes (preclinical): An IBS-relevant animal model abstract describes reduced stress-induced visceral hypersensitivity with a combined probiotic formulation; L. helveticus appears in the context of multi-strain probiotic research, but details are incomplete in the provided text.

  • Food/fermentation applications with potential health relevance: Multiple abstracts focus on L. helveticus in fermented milk/yogurt (exopolysaccharides, texture/gel properties) and a review discusses bioactive peptide generation (e.g., blood pressure-related peptides), rather than direct clinical treatment trials.

2. Does it work in treating those conditions? Summarize the evidence.

  • Acute gastroenteritis in children: No benefit shown (high-quality RCT; combination product).

    • In 886 children (3–48 months) with gastroenteritis, a 5-day course of L. rhamnosus R0011 + L. helveticus R0052 did not reduce moderate-to-severe gastroenteritis within 14 days: 26.1% (probiotic) vs 24.7% (placebo), OR 1.06 (95% CI 0.77–1.46), P=0.72.

    • No significant differences in diarrhea duration, vomiting duration, unscheduled healthcare visits, or adverse events.

  • Pediatric AGE guideline conclusion: Evidence supports “against” this strain combination.

    • The ESPGHAN Working Group made a strong recommendation against L. helveticus R0052 + L. rhamnosus R0011 for treating AGE in children, with moderate certainty of evidence.

  • Cadmium toxicity (rats): Suggestive benefit, but not directly translatable to humans and not isolate-specific.

    • A 30-day rat study using a mix (including L. helveticus) reported improved oxidative stress markers (lower lipid peroxides/MDA; higher SOD and CAT), improved histopathology in intestine and lung, and gene-expression changes consistent with reduced inflammation (down-regulated TNF-α and IL-6) compared with Cd-only animals.

    • Limitation: multi-strain mixture prevents attributing effects specifically to L. helveticus; animal model.

  • BV-related outcomes (pilot vaginal suppository): Symptom and pH/Nugent improvements, but L. helveticus not proven as the causal agent.

    • In a 28-day pilot RCT of a multi-Lactobacillus vaginal suppository, vaginal pH, itching score, and Nugent score decreased and vaginal health index improved; microbiome analysis identified L. helveticus as an indicator species occurring differentially in the treated group.

    • Limitations: multi-species product; pilot size; outcomes improved vs baseline and compared with placebo for some measures, but the abstract does not isolate the effect of L. helveticus alone.

  • Immune activation (macrophage model): Demonstrates biological activity, not clinical efficacy.

    • L. helveticus (IMAU70129) induced pro-inflammatory cytokines and uniquely induced IL-1β (after 24h) among tested strains; increased phagocytosis/bactericidal activity; increased NF-κB pp65 nuclear translocation and TLR2-dependent signaling.

    • Limitation: in vitro immune stimulation does not establish clinical benefit and could be context-dependent (helpful vs harmful depending on condition).

3. What health benefits does it have?

  • Potential immune-supporting effects (mechanistic/in vitro evidence).

    • Human macrophage experiments show L. helveticus can stimulate innate immune functions: increased phagocytosis and bactericidal activity against pathogens (e.g., S. aureus, S. typhimurium, E. coli) and activation of NF-κB/TLR2 signaling, with induction of early cytokines (IL-8, TNF-α, IL-12p70, IL-6) and IL-1β (strain-dependent).

  • Antioxidant/anti-inflammatory protective signals in toxicant exposure (animal, multi-strain evidence).

    • In Cd-exposed rats, a probiotic mix including L. helveticus was associated with lower oxidative damage (lower MDA), higher antioxidant enzymes (SOD, CAT), reduced inflammatory gene expression (TNF-α, IL-6), and improved tissue histology in intestine and lung.

  • Potential vaginal microbiome support (human pilot; multi-strain evidence).

    • In a BV-symptom pilot trial of a multi-Lactobacillus suppository, improvements in vaginal pH, itching, Nugent score, and vaginal health index were observed; L. helveticus emerged as an indicator species after treatment, suggesting possible participation in a healthier community structure.

  • Bioactive peptide generation from dairy proteins (review-level evidence; not direct clinical proof in these abstracts).

    • A review describes L. helveticus as having a strong proteolytic system that releases peptides during milk fermentation; reported potential benefits of fermented dairy products include decreased blood pressure, immune stimulation, improved calcium absorption, and anti-virulence effects against pathogens—attributed to peptides produced during fermentation.

    • Important limitation: these are described as “studies have shown” in a review; the provided text does not give specific RCT outcomes for L. helveticus alone.

  • Food technology benefits (not a human health outcome, but relevant to functional foods).

    • Multiple abstracts show L. helveticus strains can produce exopolysaccharides (EPS) that improve fermented milk/yogurt texture, gel density, and viscosity (e.g., high EPS yield linked to superior rheology; in situ EPS filling the casein network).

4. Does it have any downsides or side effects?

  • In pediatric gastroenteritis, no clinical benefit and therefore potential “downside” is unnecessary use.

    • The large pediatric RCT found no improvement in severity, diarrhea/vomiting duration, or healthcare utilization with L. helveticus R0052 + L. rhamnosus R0011 versus placebo.

    • ESPGHAN issued a strong recommendation against this combination for AGE treatment (moderate certainty), implying that routine use is not justified for that indication.

  • Adverse events in the pediatric RCT were not increased.

    • Adverse events were similar: 34.8% (probiotic) vs 38.7% (placebo), OR 0.83 (95% CI 0.62–1.11), P=0.21.

  • Potential for pro-inflammatory signaling (mechanistic concern, context-dependent).

    • In vitro, L. helveticus strains induced early pro-inflammatory cytokines and uniquely induced IL-1β among tested strains, and activated NF-κB/TLR2 pathways in macrophages. This could be beneficial for pathogen defense but could theoretically be undesirable in conditions where inflammation is harmful; clinical relevance is not established by the abstract.

  • General probiotic cautions are not addressed in these abstracts.

    • The provided abstracts do not discuss rare risks (e.g., bloodstream infection in severely immunocompromised patients) or product quality issues; therefore no evidence-based statement can be made here from the supplied text.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are provided in the supplied abstracts.

  • No gene–probiotic interaction data: None of the abstracts report differential effects of L. helveticus by human genotype (e.g., immune variants, cytokine polymorphisms, lactase persistence, HLA types).

  • Animal gene-expression changes are not pharmacogenomics: The cadmium rat study reports changes in expression of Bax, p53, caspase 3, Bcl2, TNF-α, and IL-6 with a probiotic mix, but this reflects biological response, not genotype-specific benefit/harm.

References

  1. Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review.
    Huiying Wang, In-Seon Lee, Christoph Braun, Paul Enck (2016) - Journal of neurogastroenterology and motility
  2. ProbioticLactobacillusStrains Stimulate the Inflammatory Response and Activate Human Macrophages
    L M Rocha-Ramírez, R A Pérez-Solano, S L Castañón-Alonso, S S Moreno Guerrero, A Ramírez Pacheco (2017)
  3. Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis.
    Stephen B Freedman, Sarah Williamson-Urquhart, Ken J Farion, Serge Gouin, Andrew R Willan, Naveen Poonai, Katrina Hurley, Philip M Sherman, Yaron Finkelstein, Bonita E Lee, Xiao-Li Pang, Linda Chui, David Schnadower, Jianling Xie, Marc Gorelick, Suzanne Schuh (2018) - The New England journal of medicine
  4. A Mixture of Multi-Strain Probiotics (Lactobacillus Rhamnosus, Lactobacillus Helveticus, and Lactobacillus Casei) had Anti-Inflammatory, Anti-Apoptotic, and Anti-Oxidative Effects in Oxidative Injuries Induced By Cadmium in Small Intestine and Lung.
    Shadi Dashtbanei, Zahra Keshtmand (2023) - Probiotics and antimicrobial proteins
  5. Exploring the Potential of
    Fellipe Lopes De Oliveira, Mateus Kawata Salgaço, Marina Toscano de Oliveira, Victoria Mesa, Adilson Sartoratto, Antonio Medeiros Peregrino, Williams Santos Ramos, Katia Sivieri (2023) - Nutrients
  6. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome.
    Na Young Lee, Sang Jun Yoon, Dae Hee Han, Haripriya Gupta, Gi Soo Youn, Min Jea Shin, Young Lim Ham, Min Jung Kwak, Byung Yong Kim, Jeong Seok Yu, Do Yup Lee, Tae-Sik Park, Si-Hyun Park, Byoung Kook Kim, Hyun Chae Joung, In Suk Choi, Ji Taek Hong, Dong Joon Kim, Sang Hak Han, Ki Tae Suk (2020) - Gut microbes
  7. Antimicrobial activity and antibiotic susceptibility of
    Ralitsa Georgieva, Lyubomira Yocheva, Lilia Tserovska, Galina Zhelezova, Nina Stefanova, Akseniya Atanasova, Antonia Danguleva, Gergana Ivanova, Nikolay Karapetkov, Nevenka Rumyan, Elena Karaivanova (2015) - Biotechnology, biotechnological equipment
  8. Effect of exopolysaccharides yield and addition concentration of Lactobacillus helveticus on the processing characteristics of fermented milk and its mechanism.
    Kangyong Zhang, Sibo Liu, Hongwei Tang, Smith Etareri Evivie, Zengwang Guo, Bailiang Li (2024) - International journal of biological macromolecules
  9. Bifidobacterium longum and Lactobacillus helveticus Synergistically Suppress Stress-related Visceral Hypersensitivity Through Hypothalamic-Pituitary-Adrenal Axis Modulation.
    Afifa Ait-Belgnaoui, Isabelle Payard, Claire Rolland, Cherryl Harkat, Viorica Braniste, Vassillia Théodorou, Thomas A Tompkins (2018) - Journal of neurogastroenterology and motility
  10. Use of Probiotics for the Management of Acute Gastroenteritis in Children: An Update.
    Hania Szajewska, Alfredo Guarino, Iva Hojsak, Flavia Indrio, Sanja Kolacek, Rok Orel, Silvia Salvatore, Raanan Shamir, Johannes B van Goudoever, Yvan Vandenplas, Zvi Weizman, Bartłomiej M Zalewski (2020) - Journal of pediatric gastroenterology and nutrition
  11. Lactobacillus helveticus: the proteolytic system.
    M W Griffiths, A M Tellez (2013) - Frontiers in microbiology
  12. In situ exopolysaccharides produced by Lactobacillus helveticus MB2-1 and its effect on gel properties of Sayram ketteki yoghurt.
    Zhiwen Ge, Xuan Bao, Zhiyu Li, Xiaohong Chen, Wei Li, Xin Rui, Junjun Wu, Qiuqin Zhang, Mingsheng Dong (2022) - International journal of biological macromolecules
  13. VagiBIOM Lactobacillus suppository improves vaginal health index in perimenopausal women with bacterial vaginosis: a randomized control trial.
    Vijitha Vivekanandan, Zaiba Hasan Khan, Giriprasad Venugopal, Bhavana Musunuru, Priyanka Mishra, Shalini Srivastava, Balamurugan Ramadass, Bobban Subhadra (2024) - Scientific reports
  14. Lactobacillus helveticus KLDS1.8701 alleviates d-galactose-induced aging by regulating Nrf-2 and gut microbiota in mice.
    Bailiang Li, Smith Etareri Evivie, Jingjing Lu, Yuehua Jiao, Chengfeng Wang, Ziye Li, Fei Liu, Guicheng Huo (2018) - Food & function
  15. Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease.
    Jung A Eom, Jin-Ju Jeong, Sang Hak Han, Goo Hyun Kwon, Kyeong Jin Lee, Haripriya Gupta, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hyun Chae Joung, Kyung Hwan Kim, Dong Joon Kim, Ki Tae Suk (2023) - Gut microbes
  16. Probiotic and anti-inflammatory attributes of an isolate Lactobacillus helveticus NS8 from Mongolian fermented koumiss.
    Jingjing Rong, Houfeng Zheng, Ming Liu, Xu Hu, Tao Wang, Xingwei Zhang, Feng Jin, Li Wang (2015) - BMC microbiology
  17. The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID-19 patients: A randomized placebo-controlled trial.
    Mahsa Vaezi, Sahar Ravanshad, Mina Akbari Rad, Hossein Zarrinfar, Mona Kabiri (2023) - Journal of medical virology
  18. Understanding the bacterial communities of hard cheese with blowing defect.
    Daniela Bassi, Edoardo Puglisi, Pier Sandro Cocconcelli (2015) - Food microbiology
  19. Low molecular weight chitosan from Pleurotus ostreatus waste and its prebiotic potential.
    Divya Yadav, K V Harish Prashanth, Pradeep Singh Negi (2024) - International journal of biological macromolecules
  20. In Vivo Functional Properties of Dairy Bacteria.
    Giuseppe Aprea, Ilaria Del Matto, Patrizia Tucci, Lucio Marino, Silvia Scattolini, Franca Rossi (2023) - Microorganisms


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!